Piper Sandler lowered the firm’s price target on CME Group to $225 from $235 and keeps an Overweight rating on the shares following quarterly results. Revenues and expenses both modestly missing the firm’s estimate, buy were offset by higher non-operating income of $155M and a lower tax rate of 23.1%, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group Inc. Reports All-Time Record Revenue of $1.5 Billion for Q2 2024
- CME Upcoming Earnings Report: What to Expect?
- CME Group price target lowered to $208 from $228 at Barclays
- CME Group price target lowered to $235 from $250 at Piper Sandler
- CME Group (NASDAQ:CME): The Next Great Dividend Stock